A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Zeidner, J. F.; Foster, M. C.; Johnson, M.; Huang, Y.; Swords, R. T.; Stein, E.; Foran, J. M.; Baer, M. R.; Stock, W.; Madanat, Y. F.; Kovacsovics, T.; Olin, R. L.; Blum, W. G.; Schiller, G. J.; Lin, T. L.; Redner, R. L.; Al-Mansour, Z.; Curran, E. K.; Heerema, N. A.; Martycz, M.; Rosenberg, L.; Marcus, S.; Yocum, A. O.; Chen, T.; Stefanos, M.; Druggan, F.; Burd, A.; Levine, R. L.; Druker, B. J.; Borate, U.; Byrd, J. C.; Mims, A. S. |
| Abstract Title: | A Phase 1b dose escalation and expansion study of SNDX-5613, azacitidine (AZA) and venetoclax (VEN) in newly diagnosed, patients ≥ 60 years with untreated NPM1-mutated/ FLT3-wild type AML or KMT2A-rearranged acute myeloid leukemia (AML) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 9070 |
| End Page: | 9073 |
| Language: | English |
| ACCESSION: | WOS:000893230302031 |
| DOI: | 10.1182/blood-2022-166715 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work